News and features

Scientists at The Institute of Cancer Research, London, have identified a gene that affects how ovarian clear cell carcinoma (OCCC) could respond to a new class of drug called ATR inhibitors.

Ovarian cancer is often diagnosed late, making it difficult to treat. But innovative research at The Institute of Cancer Research, London, is changing how we think about managing this complex and hard-to-treat disease. Robbie Lockyer speaks to molecular pharmacology expert and medical oncologist Professor Udai Banerji to find out more about therapeutic research strategies.

Genetic testing to identify women with Lynch Syndrome is likely to need to increase dramatically to ensure that carriers are not missed, a new analysis by ICR researchers has found.

Researchers have carried out an in-depth analysis of 10,478 cancer genomes across 35 different cancer types, identifying 330 potential cancer-driving genes, 74 of which are newly associated with cancer. The findings highlight the potential to develop new, more targeted treatment options for cancer patients.

A combination of two drugs which can block the growth of cancer cells has shown promising results in women with a form of ovarian cancer that rarely responds to chemotherapy or hormone therapy.

Scientists have developed a new clinical pathway for testing for the cancer-causing faults in the BRCA gene that could ensure patients get the right treatment and boost the number of people who get tested.

Researchers have examined thousands of genetically defined traits to identify possible causal relationships for eight common cancers.

New research identifies specific genetic changes that can increase someone's risk of breast and ovarian cancers, to help guide clinical decision-making

An innovative cancer drug discovered by scientists at The Institute of Cancer Research, London, is set to enter a new clinical trial.

A new, oral ‘first in class’ experimental cancer drug has shown potent activity against cancer cells and caused shrinkage of hard-to-treat human ovarian tumours grown in mice, a new study shows.

A drug combination targeting multiple mutant versions of cancer’s ‘death star’ protein has shown promise in a small, early-phase clinical trial for some patients with advanced lung, ovarian and thyroid cancer.

A new combination of targeted drugs for a type of ovarian cancer has shown promising results in an early clinical trial – shrinking tumours in half of patients.